InMed Pharmaceuticals (INM) Assets Average (2020 - 2026)

InMed Pharmaceuticals' Assets Average history runs 7 years deep, the most recent figure standing at $10.2 million for Q1 2026.

• On a quarterly basis, Assets Average rose 14.3% year-over-year to $10.2 million in Q1 2026; TTM through Mar 2026 was $10.2 million, a 14.3% increase from a year earlier, with the FY2025 full-year figure at $13.7 million, up 5.68% from the prior year.
• Assets Average slipped to $10.2 million in Q1 2026 per INM's latest filing, from $12.3 million in the prior quarter.
• Across five years, Assets Average topped out at $17.4 million in Q1 2022 and bottomed at $8.9 million in Q1 2025.
• The 5-year median for Assets Average is $13.1 million (2023), against an average of $13.1 million.
• Across the five-year window, Assets Average soared 44.73% in 2022 and sank 37.86% in 2025, its largest moves.
• Year by year, Assets Average stood at $15.8 million in 2022, then slipped by 16.92% to $13.1 million in 2023, then dropped by 27.53% to $9.5 million in 2024, then gained by 29.45% to $12.3 million in 2025, then slipped by 17.22% to $10.2 million in 2026.
• Per Business Quant, the three latest INM Assets Average figures stand at $10.2 million (Q1 2026), $12.3 million (Q4 2025), and $14.5 million (Q3 2025).